IN2015DN03936A - - Google Patents

Info

Publication number
IN2015DN03936A
IN2015DN03936A IN3936DEN2015A IN2015DN03936A IN 2015DN03936 A IN2015DN03936 A IN 2015DN03936A IN 3936DEN2015 A IN3936DEN2015 A IN 3936DEN2015A IN 2015DN03936 A IN2015DN03936 A IN 2015DN03936A
Authority
IN
India
Prior art keywords
plgas
pharmaceutically
acceptable salt
active ingredient
sustained release
Prior art date
Application number
Other languages
English (en)
Inventor
Holger Petersen
Markus Ahlheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN03936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN03936A publication Critical patent/IN2015DN03936A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
IN3936DEN2015 2005-12-22 2006-12-20 IN2015DN03936A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
EP06119086 2006-08-17
PCT/EP2006/012313 WO2007071395A1 (en) 2005-12-22 2006-12-20 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Publications (1)

Publication Number Publication Date
IN2015DN03936A true IN2015DN03936A (pt) 2015-10-02

Family

ID=37772904

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3936DEN2015 IN2015DN03936A (pt) 2005-12-22 2006-12-20

Country Status (22)

Country Link
US (6) US20090004283A1 (pt)
EP (3) EP2359809B1 (pt)
JP (4) JP2009520727A (pt)
KR (5) KR20130024987A (pt)
CN (1) CN103251929A (pt)
AR (1) AR058591A1 (pt)
AU (1) AU2006328950B2 (pt)
BR (2) BR122019027412B8 (pt)
CA (1) CA2631811C (pt)
CL (1) CL2018003398A1 (pt)
EC (1) ECSP088560A (pt)
ES (2) ES2492641T3 (pt)
IL (1) IL191842A0 (pt)
IN (1) IN2015DN03936A (pt)
MA (1) MA30064B1 (pt)
NO (1) NO20082988L (pt)
PE (1) PE20071139A1 (pt)
PL (2) PL2359809T3 (pt)
PT (2) PT1968549E (pt)
RU (1) RU2464972C2 (pt)
TW (2) TWI469788B (pt)
WO (1) WO2007071395A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101631475B1 (ko) 2007-06-06 2016-06-20 데비오팜 리서치 ＆ 매뉴팩처링 에스아 마이크로 입자로 구성되는 저속 방출 약학 조성물
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
ES2522342T3 (es) * 2008-01-30 2014-11-14 Novartis Ag Formulación de liberación sostenida que comprende octreótido y tres polímeros lineales de polilactida-co-glicolida
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
NZ591810A (en) * 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
EP2389161A2 (en) * 2009-01-23 2011-11-30 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US20120022137A1 (en) * 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
PL3199146T3 (pl) * 2011-04-25 2020-03-31 Shan Dong Luye Pharmaceutical Co., Ltd. Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
CN107405059B (zh) * 2015-06-26 2019-05-28 奥林巴斯株式会社 内窥镜电源供给系统
US20220000782A1 (en) * 2016-12-27 2022-01-06 Upexmed Co. Ltd. Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
US20210346296A1 (en) * 2020-05-08 2021-11-11 M. Technique Co., Ltd. A biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same
JP6810502B1 (ja) * 2020-05-08 2021-01-06 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
US11617720B2 (en) 2020-05-08 2023-04-04 M. Technique Co., Ltd. Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE2512T1 (de) * 1979-11-27 1983-03-15 Sandoz Ag Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
DK0946169T3 (da) * 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
AU742372B2 (en) * 1997-06-04 2002-01-03 Debio Recherche Pharmaceutique S.A. Implants for controlled release of pharmaceutically active principles and method for making same
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1344520B1 (en) * 2002-03-15 2007-10-03 Alrise Biosystems GmbH Microparticles and method for their production
JP2006508127A (ja) * 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
CA2819769C (en) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
KR101231856B1 (ko) * 2004-08-12 2013-02-08 큐피에스 엘엘씨 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물

Also Published As

Publication number Publication date
CA2631811A1 (en) 2007-06-28
KR20130024986A (ko) 2013-03-08
BR122019027412B1 (pt) 2020-12-01
AU2006328950A1 (en) 2007-06-28
KR20080078000A (ko) 2008-08-26
KR101245919B1 (ko) 2013-03-20
ECSP088560A (es) 2008-07-30
BR122019027412B8 (pt) 2021-07-27
WO2007071395A1 (en) 2007-06-28
KR20130024988A (ko) 2013-03-08
NO20082988L (no) 2008-08-29
TW200803921A (en) 2008-01-16
US20160120935A1 (en) 2016-05-05
US20180140662A1 (en) 2018-05-24
ES2755032T3 (es) 2020-04-21
TW201424747A (zh) 2014-07-01
IL191842A0 (en) 2008-12-29
PT1968549E (pt) 2014-08-29
EP2359809A1 (en) 2011-08-24
TWI468172B (zh) 2015-01-11
BRPI0620063B1 (pt) 2020-09-08
CL2018003398A1 (es) 2019-04-26
PL2359809T3 (pl) 2020-01-31
EP2359809B1 (en) 2019-08-14
JP2013177406A (ja) 2013-09-09
JP2016216467A (ja) 2016-12-22
ES2492641T3 (es) 2014-09-10
PL1968549T3 (pl) 2014-10-31
BRPI0620063A2 (pt) 2011-11-01
BRPI0620063B8 (pt) 2021-05-25
EP3603623A1 (en) 2020-02-05
CA2631811C (en) 2017-06-20
RU2464972C2 (ru) 2012-10-27
JP2015044823A (ja) 2015-03-12
PT2359809T (pt) 2019-11-04
CN103251929A (zh) 2013-08-21
MA30064B1 (fr) 2008-12-01
KR20130024987A (ko) 2013-03-08
AU2006328950B2 (en) 2010-07-29
US20090004283A1 (en) 2009-01-01
KR101458728B1 (ko) 2014-11-05
RU2008129626A (ru) 2010-01-27
AR058591A1 (es) 2008-02-13
EP1968549B1 (en) 2014-05-14
PE20071139A1 (es) 2007-11-16
EP1968549A1 (en) 2008-09-17
JP2009520727A (ja) 2009-05-28
US20150037420A1 (en) 2015-02-05
KR20140133968A (ko) 2014-11-20
JP6239851B2 (ja) 2017-11-29
TWI469788B (zh) 2015-01-21
JP6178772B2 (ja) 2017-08-09
US20200206306A1 (en) 2020-07-02
BRPI0620063A8 (pt) 2018-05-02
US20220296675A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
IN2015DN03936A (pt)
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
TW200716119A (en) A solid pharmaceutical dosage formulation
MX2010004576A (es) Derivados de pirimidina novedosos.
IL214617A0 (en) Use of controlled release formulations of octreotide
IL184460A0 (en) Sustained release pharmaeutical formulations
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
IL178596A0 (en) Sustained release formulations
MX2009004439A (es) Composicion de ibuprofeno.
DE602006002260D1 (de) Insektenabweisende zusammensetzungen mit verzögerter freisetzung
MX2007003196A (es) Agente y alimento para evitar/mejorar el trastorno digestivo funcional.
TW200621160A (en) Anti-termite agent
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2010008365A (es) Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
ZA200801430B (en) Storage-stable sulphonamide formulations
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
NO20065791L (no) Asyklovir-formuleringer
BRPI0417265A (pt) composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna
WO2007137216A3 (en) Gastroretentive sustained release formulations
TNSN08271A1 (en) Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
GB0401634D0 (en) A surfactant
WO2007121883A3 (de) 1,4:3,6-dianhydromannitol-derivate und deren verwendung
ZA200804629B (en) Sustained release formulation comprising octreotide and two or more polyactide-co-glycolide polymers
EP1682125A4 (en) MULTIPLE EFFECTIVE MEANS SUCH AS ANTHELMINTIKA DELIVERY WITH DELAYED RELEASE
ITMI20020639A0 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil -urea